Literature DB >> 25046692

Pivotal role of phospholipase D1 in tumor necrosis factor-α-mediated inflammation and scar formation after myocardial ischemia and reperfusion in mice.

Tanja Schönberger1, Tobias Jürgens1, Julia Müller2, Nicole Armbruster1, Christina Niermann3, Simone Gorressen2, Jan Sommer4, Huasong Tian5, Gilbert di Paolo5, Jürgen Scheller4, Jens W Fischer2, Meinrad Gawaz1, Margitta Elvers6.   

Abstract

Myocardial inflammation is critical for ventricular remodeling after ischemia. Phospholipid mediators play an important role in inflammatory processes. In the plasma membrane they are degraded by phospholipase D1 (PLD1). PLD1 was shown to be critically involved in ischemic cardiovascular events. Moreover, PLD1 is coupled to tumor necrosis factor-α signaling and inflammatory processes. However, the impact of PLD1 in inflammatory cardiovascular disease remains elusive. Here, we analyzed the impact of PLD1 in tumor necrosis factor-α-mediated activation of monocytes after myocardial ischemia and reperfusion using a mouse model of myocardial infarction. PLD1 expression was highly up-regulated in the myocardium after ischemia/reperfusion. Genetic ablation of PLD1 led to defective cell adhesion and migration of inflammatory cells into the infarct border zone 24 hours after ischemia/reperfusion injury, likely owing to reduced tumor necrosis factor-α expression and release, followed by impaired nuclear factor-κB activation and interleukin-1 release. Moreover, PLD1 was found to be important for transforming growth factor-β secretion and smooth muscle α-actin expression of cardiac fibroblasts because myofibroblast differentiation and interstitial collagen deposition were altered in Pld1(-/-) mice. Consequently, infarct size was increased and left ventricular function was impaired 28 days after myocardial infarction in Pld1(-/-) mice. Our results indicate that PLD1 is crucial for tumor necrosis factor-α-mediated inflammation and transforming growth factor-β-mediated collagen scar formation, thereby augmenting cardiac left ventricular function after ischemia/reperfusion.
Copyright © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25046692     DOI: 10.1016/j.ajpath.2014.06.005

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  16 in total

Review 1.  The phospholipase D superfamily as therapeutic targets.

Authors:  Michael A Frohman
Journal:  Trends Pharmacol Sci       Date:  2015-02-03       Impact factor: 14.819

2.  Oxidized LDL phagocytosis during foam cell formation in atherosclerotic plaques relies on a PLD2-CD36 functional interdependence.

Authors:  Ramya Ganesan; Karen M Henkels; Lucile E Wrenshall; Yasunori Kanaho; Gilbert Di Paolo; Michael A Frohman; Julian Gomez-Cambronero
Journal:  J Leukoc Biol       Date:  2018-04-14       Impact factor: 4.962

3.  Measuring Phospholipase D Enzymatic Activity Through Biochemical and Imaging Methods.

Authors:  F Philip; E E Ha; M A Seeliger; M A Frohman
Journal:  Methods Enzymol       Date:  2016-10-22       Impact factor: 1.600

4.  Biallelic loss-of-function variants in PLD1 cause congenital right-sided cardiac valve defects and neonatal cardiomyopathy.

Authors:  Najim Lahrouchi; Alex V Postma; Christian M Salazar; Daniel M De Laughter; Fleur Tjong; Lenka Piherová; Forrest Z Bowling; Dominic Zimmerman; Elisabeth M Lodder; Asaf Ta-Shma; Zeev Perles; Leander Beekman; Aho Ilgun; Quinn Gunst; Mariam Hababa; Doris Škorić-Milosavljević; Viktor Stránecký; Viktor Tomek; Peter de Knijff; Rick de Leeuw; Jamille Y Robinson; Sabrina C Burn; Hiba Mustafa; Matthew Ambrose; Timothy Moss; Jennifer Jacober; Dmitriy M Niyazov; Barry Wolf; Katherine H Kim; Sara Cherny; Andreas Rousounides; Aphrodite Aristidou-Kallika; George Tanteles; Bruel Ange-Line; Anne-Sophie Denommé-Pichon; Christine Francannet; Damara Ortiz; Monique C Haak; Arend D.J. Ten Harkel; Gwendolyn Tr Manten; Annemiek C Dutman; Katelijne Bouman; Monia Magliozzi; Francesca Clementina Radio; Gijs We Santen; Johanna C Herkert; H Alex Brown; Orly Elpeleg; Maurice Jb van den Hoff; Barbara Mulder; Michael V Airola; Stanislav Kmoch; Joey V Barnett; Sally-Ann Clur; Michael A Frohman; Connie R Bezzina
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 5.  Physiological and pathophysiological roles for phospholipase D.

Authors:  Rochelle K Nelson; Michael A Frohman
Journal:  J Lipid Res       Date:  2015-04-29       Impact factor: 5.922

6.  D-series Resolvins activate Phospholipase D in phagocytes during inflammation and resolution.

Authors:  Ramya Ganesan; Karen M Henkels; Krushangi Shah; Xavier De La Rosa; Stephania Libreros; Nagarjuna R Cheemarla; Charles N Serhan; Julian Gomez-Cambronero
Journal:  FASEB J       Date:  2020-10-12       Impact factor: 5.191

Review 7.  Phospholipid signaling in innate immune cells.

Authors:  Valerie B O'Donnell; Jamie Rossjohn; Michael Jo Wakelam
Journal:  J Clin Invest       Date:  2018-04-23       Impact factor: 14.808

8.  Phospholipase D2 loss results in increased blood pressure via inhibition of the endothelial nitric oxide synthase pathway.

Authors:  Rochelle K Nelson; Jiang Ya-Ping; John Gadbery; Danya Abedeen; Nicole Sampson; Richard Z Lin; Michael A Frohman
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

Review 9.  Phospholipase D and Its Essential Role in Cancer.

Authors:  Ju Hwan Cho; Joong-Soo Han
Journal:  Mol Cells       Date:  2017-11-16       Impact factor: 5.034

Review 10.  Mammalian phospholipase D: Function, and therapeutics.

Authors:  M I McDermott; Y Wang; M J O Wakelam; V A Bankaitis
Journal:  Prog Lipid Res       Date:  2019-12-09       Impact factor: 16.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.